ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
A phase 2 trial of Elacestrant in HR-positive / HER2-negative breast cancer, run by Stemline Therapeutics, Inc., active and no longer recruiting.
Overview
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study is a phase 2 interventional study registered as NCT05596409 by Stemline Therapeutics, Inc., with 61 participants enrolled, started 2023-05-19 and due to reach its primary completion in 2026-11. Interventions recorded: Elacestrant.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialStudy of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Shares Menarini / Stemline and the tag pipeline.
- TrialStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Shares Elacestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.